Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murepavadin plus one anti-pseudomonal antibiotic versus two anti-pseudomonal antibiotics for ventilator-associated bacterial pneumonia caused by suspected or confirmed Pseudomonas aeruginosa
MOH_2018-01-11_001947Phase 3Not yet recruiting
- Sponsor
- Polyphor
- Start
- Dec 2017
- Modality
- Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of murepavadin in ventilator-associated pneumonia (VAP) and Pseudomonas pneumonia (2 arms), sponsored by Polyphor. Primary endpoint: Primary endpoint not reported. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
murepavadin
03
Conditions
ventilator-associated pneumonia (VAP)Pseudomonas pneumonia
Beyond the preview
Go deeper on MOH_2018-01-11_001947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-11_001947.